Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4384657 | 0.85 | HTT (0.43) | LMNAALDH1A1POLBMEN1KMT2A | |
| SCHEMBL4393726 | 0.84 | SMN1; SMN2 (0.41) | ALDH1A1MEN1KMT2ASMN1; SMN2CD274 | |
| SCHEMBL4385587 | 0.83 | NPSR1 (0.37) | LMNAALDH1A1POLBMEN1KMT2A | |
| SCHEMBL4381665 | 0.82 | LMNA (0.51) | LMNAALDH1A1POLBMEN1KMT2A | |
| SCHEMBL4386807 | 0.81 | QPCT (0.41) | LMNAALDH1A1CD274 | |
| SCHEMBL4384965 | 0.78 | ALDH1A1 (0.43) | ALDH1A1POLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4389553 | 0.76 | EGFR (0.40) | ALDH1A1POLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4395260 | 0.75 | ALDH1A1 (0.41) | ALDH1A1POLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4388212 | 0.74 | ALDH1A1 (0.40) | ALDH1A1POLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4383921 | 0.74 | ALDH1A1 (0.42) | ALDH1A1POLBMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1704856-A1 | HSP90 FAMILY PROTEIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | LMNA 4706/4885ALDH1A1 3520/4885POLB 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.